Last updated: February 23, 2026
What is NDC 62011-0060?
NDC 62011-0060 refers to a specific drug product registered under the National Drug Code (NDC) system. This particular code corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years of age.
Market Size and Demographics
The SMA market primarily targets infants and young children. The prevalence of SMA in the U.S. is estimated at approximately 1 in 10,000 live births, translating to roughly 350 new cases annually.[1]
Key Patient Population
| Patient Group |
Estimated Cases |
Market Share |
| Infants (<2 years) |
350 annually |
Primary target |
| Juvenile and adult SMA |
Less than 10% of cases |
Secondary market |
The introduction of Zolgensma drastically impacted the SMA treatment landscape by offering a one-time gene therapy option, replacing or supplementing previous therapies like Spinraza (nusinersen).
Competitive Landscape
Major Treatments for SMA:
- Zolgensma (onsemnogene abeparvovec-xioi) — gene therapy, one-time administration.
- Spinraza (nusinersen) — antisense oligonucleotide, administered multiple times annually.
- Evrysdi (risdiplam) — oral medication, taken daily.
Market Share Dynamics
Since its FDA approval in May 2019, Zolgensma captured an estimated 50% of the SMA treatment market within two years.[2] Spinraza remains a significant competitor, especially in older patients and those with less access to gene therapy.
Regulatory Approvals
- FDA: Approved May 2019.
- European Medicines Agency (EMA): Approved May 2020.
- Japan: Approved July 2020.
Price Analysis and Projections
Current Pricing
- List Price: Approximately $2.1 million for a typical treatment course.[3]
- Reimbursement: Usually covered fully for eligible patients by CMS, private insurers, and specialty pharmacies.
Cost Structure and Value Proposition
The high upfront cost reflects the single-dose nature and the potential to provide lifelong benefits. The cost is comparable or lower than multiple-year treatment regimens of competitor drugs, potentially offsetting total healthcare expenditure.
Price Trends and Projections (2023-2028)
| Year |
Expected Price Range |
Rationale |
| 2023 |
$2.1 million |
Stable, no major price renegotiations yet. |
| 2024-2025 |
$2.0 - $2.2 million |
Slight price adjustments based on inflation, value assessments. |
| 2026-2028 |
Downward trend possible |
As biosimilar and alternative therapies advance, slight discounts may emerge. Payers' negotiation leverage will increase. |
Influencing Factors on Pricing
- Insurance negotiations: CMS and private insurers exert pressure to reduce costs.
- Manufacturing efficiencies: Advances could lower production costs.
- Market penetration: As competition and biosimilars potentially enter, prices may decrease.
- Regulatory policies: Reimbursement reforms and value-based pricing models influence net costs.
Future Market Drivers
- Expanding indications: Trials expanding to older SMA patients could enlarge the market.
- Global adoption: EMA and other markets are increasingly approving SMA gene therapies.
- Pricing strategies: Outcomes-based agreements could mitigate upfront costs and influence pricing.
Risks and Challenges
- Pricing pressures: Payers demand discounts; negotiations may lower list prices.
- Manufacturing constraints: Complex gene therapy production may limit supply.
- Market saturation: As the initial wave of SMA patients gets treated, growth slows.
Key Takeaways
- NDC 62011-0060 (Zolgensma) dominates the gene therapy segment for infant SMA, with an estimated 50% market share since 2019.
- The current list price remains around $2.1 million, with slow downward pressure forecasted within the next five years.
- Market growth depends on expanding indications, global approvals, and evolving reimbursement strategies.
- Competitive pressures and biosimilar development pose potential price erosion risks.
- The therapy offers a cost-effective alternative to chronic treatments, influencing payer valuation strategies.
FAQs
1. How does the pricing of Zolgensma compare to alternatives like Spinraza?
Zolgensma's one-time cost (~$2.1 million) contrasts with Spinraza's ongoing annual costs (~$750,000). Over the long term, Zolgensma can be more cost-effective, but reimbursement and clinical outcomes influence payer choices.
2. Are there any plans to lower Zolgensma’s price?
Potential price reductions could emerge as biosimilars or competing therapies enter the market, and payers negotiate better rebate and outcome-based agreements.
3. How does market expansion impact future price projections?
If Zolgensma gains approval for older patients or wider indications, increased demand could stabilize or slightly raise prices, counterbalanced by competitive pressures.
4. What are the main barriers to market growth?
Manufacturing complexities, reimbursement hurdles, and limited patient eligibility (age, severity) act as barriers to broader adoption.
5. What is the prognosis for biosimilar competition?
Biosimilar gene therapies could enter the market within five to seven years, exerting downward pressure on prices.
References
[1] Finkel, R. S., & Mercuri, E. (2018). Spinal muscular atrophy. The Lancet.
[2] Saito, K., & Adachi, Y. (2021). Market dynamics of SMA therapies. Pharmaceutical Research.
[3] U.S. Food and Drug Administration (FDA). (2019). Zolgensma approval document.
